Rock Point Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Rock Point Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$294K	Hold	380	–	–	0.08%	93
2025 Q4	$293K	Hold	380	–	–	0.07%	95
2025 Q3	$214K	Buy	+380	New	+$215K	0.06%	109
2025 Q2	–	Sell	-380	Closed	-$241K	–	114
2025 Q1	$241K	Hold	380	–	–	0.07%	93
2024 Q4	$271K	Hold	380	–	–	0.08%	88
2024 Q3	$399K	Hold	380	–	–	0.11%	78
2024 Q2	$399K	Hold	380	–	–	0.12%	77
2024 Q1	$366K	Hold	380	–	–	0.11%	77
2023 Q4	$334K	Sell	380 -20	-5%	-$16.5K	0.1%	75
2023 Q3	$329K	Buy	+400	New	+$314K	0.11%	78

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Rock Point Advisors's REGN Position: Q1 2026 in Review

Rock Point Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 380 shares worth $294K. The position accounts for 0.08% of the portfolio, ranked #93.

Rock Point Advisors first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $399K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Rock Point Advisors held 380 shares of Regeneron Pharmaceuticals worth $294K as of Q1 2026.
Rock Point Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.08% of Rock Point Advisors's portfolio in Q1 2026, its #93 holding.
Rock Point Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
Rock Point Advisors's Regeneron Pharmaceuticals position peaked at $399K in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Rock Point Advisors's 13F filing for Q1 2026, filed 14 May 2026.